XFOR חוב כולל להון X4 Pharmaceuticals, Inc

The X4 Pharmaceuticals (XFOR) price chart demonstrates a total debt-to-equity ratio of 0.47. Business revenues are based on the market launch of mavorixafor, an innovative treatment for WHIM syndrome. The company is currently focusing on independent promotion within US medical centers and distribution partnerships. Leading immunology experts, attracted by large-scale investments in scientific research, are driving this success.

This indicator measures the degree of financial leverage by comparing total credit obligations against net assets to assess the stability of the financing structure. Analyzing the total debt-to-equity ratio determines how effectively X4 Pharmaceuticals (XFOR) utilizes borrowed funds to scale its immunological ecosystem and ensure long-term care for a patient base with rare blood pathologies.